Fine-needle Heat Treatment Plus Eye Injection for Corneal Blood Vessel Growth
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a combination of two treatments—a heat procedure and a medication injection—to reduce abnormal blood vessel growth on the clear front surface of your eye (cornea). The goal is to improve your vision and prevent further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with corneal neovascularization (abnormal blood vessel growth on the cornea) affecting at least one section of your eye
- Your condition has been stable for at least 4 weeks with no worsening
- You are not pregnant or breastfeeding
- You have no active eye infection or recent eye surgery (within 3 months)
- You can attend follow-up appointments at the clinic regularly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of giving the medicine bevacizumab in the eye: into the front part (intracameral) versus deeper inside (intravitreal). It aims to see which approach better controls neovascular glaucoma and helps vision, especially when surgery (trabeculectomy) is needed.
This trial studies corneal crosslinking to treat active inflammation or infection that leads to new blood vessels growing into the cornea. It may help reduce ongoing damage and lower the risk of problems, including issues that can threaten a future corneal transplant.
This study looks at how repeated eye injections of a drug called bevacizumab affect chemicals in your blood that relate to heart health and inflammation. Researchers want to understand if these eye injections might impact your cardiovascular risk.
This study tests whether injecting an anti-VEGF medication directly into the clear part of your eye (cornea) can safely reduce abnormal blood vessels caused by a herpes virus eye infection. If you have HSV keratitis with new vessel growth and haven't had prior anti-VEGF treatment or corneal surgery, this trial may be an option for you.
This trial uses advanced imaging and artificial intelligence to predict how well patients with myopic macular neovascularization (a complication of severe nearsightedness) will respond to anti-VEGF injections over time. The goal is to identify who will benefit most from ongoing treatment.
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
Hear when a new Corneal Neovascularisation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.